Bobak R. Azamian Sells 3,904 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Rating) CEO Bobak R. Azamian sold 3,904 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $15.11, for a total transaction of $58,989.44. Following the transaction, the chief executive officer now owns 1,124,613 shares of the company’s stock, valued at approximately $16,992,902.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tarsus Pharmaceuticals Trading Down 0.2 %

Shares of TARS opened at $14.54 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.40 and a current ratio of 16.40. The company has a 50-day moving average of $15.84 and a two-hundred day moving average of $16.05. Tarsus Pharmaceuticals, Inc. has a 12-month low of $10.80 and a 12-month high of $21.47.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative net margin of 324.99% and a negative return on equity of 34.24%. As a group, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Dimensional Fund Advisors LP grew its holdings in shares of Tarsus Pharmaceuticals by 221.0% during the first quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock worth $485,000 after buying an additional 19,865 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Tarsus Pharmaceuticals by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after purchasing an additional 1,402 shares during the period. UBS Group AG grew its holdings in Tarsus Pharmaceuticals by 37.0% in the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after purchasing an additional 1,142 shares during the period. Invesco Ltd. grew its holdings in Tarsus Pharmaceuticals by 17.1% in the first quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock valued at $471,000 after purchasing an additional 4,078 shares during the period. Finally, State Street Corp grew its holdings in Tarsus Pharmaceuticals by 2.4% in the first quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after purchasing an additional 3,141 shares during the period. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer cut their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a research report on Thursday, November 10th.

Tarsus Pharmaceuticals Company Profile

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Stories

Insider Buying and Selling by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.